[EN] 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXYPYRROLIDINE-2-CARBOXA|MIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA<br/>[FR] DÉRIVÉS DE 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACÉTYL)-4-HYDROXYPYRROLIDINE-2-CARBOXAMIDE SERVANT D'INHIBITEURS DE VHL POUR LE TRAITEMENT DE L'ANÉMIE
申请人:[en]GENENTECH, INC.
公开号:WO2022104345A1
公开(公告)日:2022-05-19
The present disclosure relates to l-(2-(4-cyclopropyl-lH-l,2,3- triazol-l-yl)acetyl)-4-hydroxypyrrolidine-2-carboxamide derivatives and structurally related compounds of formula (I) as VHL inhibitors for the treatment of e.g. anemia (e.g. chronic anemia or anemia associated with chronic kidney disease, dialysis or cancer chemotherapy), ischemia, stroke or damage to the cardiovascular system during ischemia, or for enhancing wound healing, reducing scarring, or enhancing angiogenesis or arteriogenesis. Exemplary compounds are e.g.: • 1 -(2-(4-cyclopropyl- lH-l,2,3-triazol-l -yl)-3,3-dimethylbutanoyl)-4- hydroxypyrrolidine-2-carboxamide; • 1 -(2-(4-cyclopropyl- 1H-1,2,3 -triazol-1 -yl)-3,3 -dimethylbutanoyl) -4-hydroxy-N-methylpyrrolidine-2-carboxamide; • 1 -(2-cyclohexyl-2-(4-cyclopropyl- lH-l,2,3-triazol-l -yl)acetyl)-4- hydroxy-N-methylpyrrolidine-2-carboxamide; • 1 -(3,3 -dimethyl-2-( lH-l,2,3-triazol-l -yl)butanoyl)-4-hydroxy-N- methylpyrrolidine-2-carboxamide; • l-(2-( 4-cyclopropyl-lH-l,2,3-triazol-l-yl)-2-(l-methylcyclohexyl) acetyl)-4-hydroxy-N-methylpyrrolidine-2-carboxamide; • l-(2-( 4-cyclopropyl-lH-l,2,3-triazol-l-yl)-2-(tetrahydro-2H-pyran-4- yl)acetyl)-4-hydroxy-N-methylpyrrolidine-2-carboxamide.